2012 A Key Year For Astellas, Says New CEO Yoshihiko Hatanaka
This article was originally published in PharmAsia News
Executive Summary
Astellas is on the verge of significantly increasing its heretofore small presence in oncology in the U.S. and abroad as it, along with its partners, prepares to file one and possibly two NDAs, including for the promising prostate cancer treatment MDV3100.
You may also be interested in...
Astellas Fortifies Vesicare And Mirabegron; Looks For Organic Growth In Emerging Markets
TOKYO - Unlike its top rival Takeda Pharmaceuticals Co. Ltd., Astellas Pharma Inc. says it will primarily look for organic growth in emerging markets, although the Japanese major is not adverse to M&A if it finds the right opportunity
Astellas Pays $125 Million Up-Front To Share Rights To AVEO's Tivozanib
Astellas Pharma Inc. has fortified its oncology business by striking a deal to share development and commercialization of AVEO Pharmaceuticals Inc.'s Phase III cancer drug tivozanib in territories beyond Asia
Astellas Extends Deal With Regeneron For Antibody Technology Built Around Growing Oncology Portfolio
TOKYO - Astellas has acknowledged that it is a late-comer to the oncology space, but an extension of a non-exclusive license to Regeneron's VelocImmune technology, potentially through 2023, signals the Japanese company's continued effort to become a significant player in the monoclonal antibody space